NeurologyLive

October is over and November is here, which means it's time to turn over your calendars and check out the latest edition of #TheAxon newsletter!

At #AANEM 2024, Melissa Spencer, PhD, of UCLA Health, discussed the critical considerations when deciding appropriate patients for gene therapies, specifically AAV vectors, in treating muscular dystrophies. #Gene Therapy #MuscularDystrophy #Neuromuscular American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)

ICYMI: In our latest Mind Moments? podcast episode, Lara Jehi, MD, MHCDS, of Cleveland Clinic, discussed a recently published study that explored using machine learning algorithms to predict seizure control after #epilepsy surgery. https://lnkd.in/e6zrge76

Months after the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion for the approval of lecanemab, an antiamyloid treatment for early-stage #AlzheimerDisease, the agency has flipped course, adopting a positive opinion for recommending approval. Eisai Co., Ltd. https://lnkd.in/e-uxWsQd

In this episode, Michael Levy, MD, PhD, discusses how AQP4-IgG+ NMOSD is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have demonstrated efficacy in managing NMOSD, offering a valuable treatment option. https://lnkd.in/e2Kn9RSz

Here's the latest multidisciplinary #MultipleSclerosis research from the International Journal of MS Care (IJMSC)! CMSC ?? A study from Brazil found a high prevalence of preexisting conditions like cardiovascular issues, migraines, psychiatric disorders, autoimmune diseases, and respiratory pathologies in individuals with #MS. ?? A study from the University of North Carolina Hospitals Neurology Clinic examined factors impacting the timely initiation of DMT in patients with a new diagnosis of MS or those transitioning care providers. ?? A case report from Iran shows that an occupation-based intervention can be used for individuals with MS. ?? A study from the University of Washington found that individuals with a history of trauma and more severe physical disabilities perceived a higher risk of being targeted, with AD use amplifying this perception. ?? An exploratory study examined the effectiveness of monthly telecoaching for individuals with MS following inpatient multidisciplinary rehabilitation. Come back next month for more research from the IJMSC community or check out the website for the latest at any time!

Exciting news in Parkinson’s research! ?? Vanqua Bio announced positive interim results from the phase 1a trial of VQ-101, an oral brain-penetrant allosteric activator of glucocerebrosidase (GCase). The study demonstrated target engagement in healthy volunteers at both single and multiple ascending doses. Building on these findings, the phase 1b trial will soon begin in Parkinson’s patients, with data expected in 2025. A promising step forward for neurodegenerative disease therapies! ?? #Neurology #ParkinsonsResearch #Innovation https://lnkd.in/eyMieAxH

????Today we also spoke with MaryAnn Mays, MD, of Cleveland Clinic, who shared her post perspective on the recently concluded 2024 Scottsdale Headache Symposium! Be on the lookout for the video of the conversation coming soon! #AHSAZ #Headache #Migraine #Neurology American Headache Society

???This morning, we had a conversation with Henri Ford, MD, MHA, dean and chief academic officer at University of Miami Miller School of Medicine, who talked about how a $30 million investment will aim to advance research in #neuroscience and #aging. Stay tuned for the interview coming soon!??????

According to a recent announcement, patient recruitment for the high-dose cohort of a phase 2 study assessing oral fasudil (Bravyl; Woolsey Pharmaceuticals), a stroke therapy in development for ALS, is now complete. Study results from this group, who will receive 300 mg/day doses of fasudil, are expected to be released by mid-2025. https://lnkd.in/ej7xUBd2